Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer

[1]  Shankun Zhao,et al.  Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis , 2020, Urologia Internationalis.

[2]  C. Porta,et al.  Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial , 2020, Journal for ImmunoTherapy of Cancer.

[3]  Y. Miyagi,et al.  Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma , 2020, Cancer Immunology, Immunotherapy.

[4]  Y. Oda,et al.  PD-L1/IDO1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features. , 2020, Human pathology.

[5]  R. Motzer,et al.  Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  G. Sauter,et al.  High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma , 2020, World Journal of Urology.

[7]  W. Linehan,et al.  Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma , 2020, Journal of Cancer.

[8]  G. Sauter,et al.  Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms , 2020, Cellular Oncology.

[9]  G. Cerqueira,et al.  Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma , 2020, Journal for ImmunoTherapy of Cancer.

[10]  R. Garje,et al.  Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence , 2020, Cancers.

[11]  M. Allaf,et al.  Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma , 2020, Histopathology.

[12]  P. Tan,et al.  PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas , 2020, Journal of Clinical Pathology.

[13]  Ran-yi Liu,et al.  HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma , 2020, Journal for ImmunoTherapy of Cancer.

[14]  E. Herpel,et al.  Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma , 2019, Translational oncology.

[15]  Yeon Ju Lee,et al.  PD‐L1 expression and infiltration by CD4+ and FoxP3+ T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis , 2019, Histopathology.

[16]  J. Cheville,et al.  Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma , 2019, Cancer medicine.

[17]  F. Saad,et al.  A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. , 2019, Clinical genitourinary cancer.

[18]  B. Dai,et al.  The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma , 2019, Frontiers in Oncology.

[19]  M. Duffy,et al.  Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. , 2019, Clinical chemistry.

[20]  P. Spiess,et al.  Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies , 2019, Therapeutic advances in urology.

[21]  S. Sundaram,et al.  Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma , 2019, Asian Pacific journal of cancer prevention : APJCP.

[22]  G. Freeman,et al.  PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN , 2019, Clinical Cancer Research.

[23]  B. Melichar,et al.  Negative prognostic significance of primary cilia, CD8+ tumor infiltrating lymphocytes and PD1+ cells expression in clear cell renal cancer. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[24]  X. Ren,et al.  Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma , 2019, Front. Oncol..

[25]  M. Oya,et al.  Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma , 2019, Cancer science.

[26]  M. Fiorentino,et al.  PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[27]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[28]  M. Alsharedi,et al.  Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies , 2019, Journal of Gastrointestinal Cancer.

[29]  A. Addeo,et al.  Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis , 2019, Front. Oncol..

[30]  Y. Ouyang,et al.  Immune infiltration in renal cell carcinoma , 2019, Cancer science.

[31]  Ning Zhang,et al.  Differential Expression of PD‐L1 Between Sporadic and VHL‐Associated Hereditary Clear‐Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features , 2019, Clinical genitourinary cancer.

[32]  R. Ramsay,et al.  Prognostic Impact of Tumor-Infiltrating Lymphocytes in Primary and Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis , 2019, Diseases of the colon and rectum.

[33]  J. Spicer,et al.  Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma , 2019, Front. Immunol..

[34]  J. Zhang,et al.  Differential expression of PD-L1 between sporadic and VHL-associated hereditary clear cell renal cell carcinoma and its correlation with clinicopathological features , 2019, European Urology Supplements.

[35]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[36]  B. Rini,et al.  Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens , 2018, American journal of clinical pathology.

[37]  P. Spiess,et al.  Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma , 2018, Journal of kidney cancer and VHL.

[38]  G. Sauter,et al.  Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. , 2018, Urologic oncology.

[39]  T. Choueiri,et al.  Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] , 2018, European journal of cancer.

[40]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[41]  A. Ardıçoğlu,et al.  Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression , 2018, Diagnostic Pathology.

[42]  Junjie Xing,et al.  CD8+CXCR5+ T cells in tumor-draining lymph nodes are highly activated and predict better prognosis in colorectal cancer. , 2018, Human immunology.

[43]  K. Inamura.  Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification , 2017, International journal of molecular sciences.

[44]  J. Joo,et al.  The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry , 2017, PloS one.

[45]  B. Dai,et al.  PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness , 2017, Scientific Reports.

[46]  P. Validire,et al.  Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[47]  L. Terracciano,et al.  The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer , 2017, Clinical Cancer Research.

[48]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[49]  Y. Oda,et al.  PD-L1 expression in papillary renal cell carcinoma , 2017, BMC Urology.

[50]  W. Weichert,et al.  PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception? , 2016, Medical Oncology.

[51]  A. Großhennig,et al.  Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC) , 2016, Medical Oncology.

[52]  Su-Jin Shin,et al.  Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status , 2016, Annals of Surgical Oncology.

[53]  M. Srougi,et al.  PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis , 2015, Diagnostic Pathology.

[54]  T. Ho,et al.  PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation , 2015, Cancer Immunology Research.

[55]  G. Sauter,et al.  High intratumoral FOXP3⁺ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer. , 2015, International journal of clinical and experimental pathology.

[56]  G. Freeman,et al.  Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma , 2015, Cancer Immunology Research.

[57]  R. Herbst,et al.  Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.

[58]  Sylvia Tippmann,et al.  Programming tools: Adventures with R , 2014, Nature.

[59]  G. Freeman,et al.  PD-L1 expression in nonclear-cell renal cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[61]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[64]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[65]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[66]  C. Walleck,et al.  Trauma nursing: past, present, and future. , 1988, Maryland medical journal.

[67]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[68]  G. Freeman,et al.  PD-L 1 expression in nonclear-cell renal cell carcinoma , 2014 .

[69]  J. Cheville,et al.  Tumor B 7-H 1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up , 2006 .